BDR Pharma is set to acquire a stake in Acme’s oral solid formulations business, with reports describing the transaction as a majority-stake purchase covering the unit’s oral products.

Outlet coverage focuses on deal scope rather than operational changes. Business Line says the transaction values the business at about ₹2,370 crore (about $250 million), citing sources close to the deal, while The Hindu frames the development as BDR Pharma acquiring a stake in Acme’s oral solid formulations business. The differing emphasis mainly reflects how each outlet characterises the acquisition—stake versus majority stake—and the level of valuation detail provided.

Both accounts treat the announcement as an acquisition move by BDR Pharma to expand its footprint in oral formulations/oral care-related activities tied to Acme’s business.